Table 3 Sensitization potential of selenoesters against the Adriamycin-resistant human ovarian carcinoma cell line HOC/ADR. Tested compounds were applied in single dose (IC10) and Adriamycin in the indicated concentration range (0.1–20 µM) in order to determine its concentration halving the cell viability (IC50). Fold change was calculated as the ratio of IC50 of Adriamycin and IC50 of Adriamycin in the presence of IC10 dose of compounds.

From: Ketone-selenoesters as potential anticancer and multidrug resistance modulation agents in 2D and 3D ovarian and breast cancer in vitro models

Cpd

IC10 of compounds (µM)

IC50 of adriamycin (µM)

Fold change

K1

1.5

1.8 ± 0.1b

(1.3 ± 0.1)×

K2

1.0

2.1 ± 0.0b

(1.2 ± 0.0)×

K3

2.0

1.7 ± 0.1b

(1.4 ± 0.1)×

K4

2.9

1.8 ± 0.0b

(1.4 ± 0.1)×

K5

1.5

4.5 ± 0.1c

(0.5 ± 0.1)×

K6

1.3

2.2 ± 0.1b

(1.1 ± 0.1)×

K7

1.8

0.4 ± 0.6a

(5.9 ± 0.6)×

K8

3.0

2.2 ± 0.0b

(1.1 ± 0.1)×

N1

2.5

8.7 ± 0.9e

(0.3 ± 0.1)×

N2

3.0

2.1 ± 0.1b

(1.2 ± 0.1)×

N3

3.1

2.0 ± 0.0b

(1.3 ± 0.0)×

N4

2.4

2.0 ± 0.1b

(1.3 ± 0.1)×

N5

2.5

2.1 ± 0.2b

(1.2 ± 0.2)×

N6

2.6

6.5 ± 0.2d

(0.4 ± 0.0)×

N7

3.1

2.3 ± 0.1b

(1.1 ± 0.1)×

ADR

–

2.5 ± 0.0b

–

  1. Data are expressed as the average inhibitory concentrations (IC50) or fold change of three repetitions with standard error of the mean (SEM). Fold change higher than 1 indicated the synergistic effect of cytotostatic and tested compound. The statistical differences between compounds were calculated by one-way analysis of variance (ANOVA) and Duncan’s post hoc test (p ˂ 0.05), where the significances were denoted by different letters (a–e).
  2. Significant values are in [bold].
Back to article page